PharmacoEconomics & Outcomes News

, Volume 813, Issue 1, pp 32–32 | Cite as

Tyrosine kinase inhibitors cost effective for CML

Clinical study


  1. Fu J, et al. Economic Evaluations of Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia in Middle- and High-Income Countries: A Systematic Review. Clinical Drug Investigation : 19 Sep 2018. Available from: URL:

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations